Kymera Therapeutics To Announce Results From BROADEN2 Phase 2b Clinical Trial Evaluating KT-621, Oral STAT6 Degrader, In Patients With Atopic Dermatitis On November 23
Benzinga Newsdesk 8 hours ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026WATERTOWN, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage
Company to host video conference call and webcast at 8:00 a.m. ET on Monday, November 23, 2026
WATERTOWN, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the BROADEN2 Phase 2b clinical trial evaluating KT-621, its oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD) on Monday, November 23, 2026. A press release detailing the results will be issued at 7:00 a.m. ET, followed by a video conference call and webcast at 8:00 a.m. ET.
